Table 1 Basic characteristics of disease-free controls and groups of the HALT-C participant

N

38

37

39

n/a

Male (%)

68

59

72

0.502

Race (CA/AA)

20/12^b

30/7

28/11

0.106

Age

49.3 ± 7.7

50.1 ± 7.1

50.9 ± 6.5

0.614

IFN treatment (yes/no)

n/a

13/24

12/27

0.686

ALT (U/L)

n/a

89.1 ± 41.3

129.7 ± 69.5

0.007

AST (U/L)

n/a

67.4 ± 25.6

110.0 ± 65.0

0.002

Platelet (10⁹/L)

n/a

191.2 ± 59.4

144.7 ± 57.4

<0.001

Albumin (g/dL)

n/a

4.0 ± 0.3

3.8 ± 0.4

0.115

AFP (ng/mL)

n/a

11.7 ± 14.7

22.9 ± 24.6

0.005

Alkaline phosphatase (U/L)

n/a

91.7 ± 29.6

123.6 ± 52.1

0.636

INR

n/a

1.0 ± 0.1

1.1 ± 0.1

<0.001

Bilirubin (mg/dL)

n/a

0.7 ± 0.4

0.9 ± 0.4

0.039

Creatinine (mg/dL)

n/a

0.8 ± 0.1

0.9 ± 0.2

0.936

MELD

n/a

6.8 ± 1.3

7.5 ± 1.4

0.006

APRI

n/a

0.9 ± 0.5

2.4 ± 2.5

<0.001

FIB-4

n/a

2.1 ± 1.1

3.5 ± 2.7

<0.001